Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2005

View Archived Issues

Allopregnanolone shows efficacy in a rat model of spontaneous recurrent seizures

Analogues of etodolac from Salmedix for MM

A3R agonism effective for cholangiocarcinoma

Trend toward positive survival benefit in patients treated with Zadaxin plus TACE

BioCryst cleared to study intravenous peramivir in phase I

Updated antibacterial efficacy of tebipenem pivoxil presented at ICAAC

New phase I/II trial of intravenous Fodosine in B-cell ALL

SPA agreement for phase III study of ramoplanin

Sirna selects Sirna-AV34 as development candidate for hepatitis C

Exelixis and Wyeth sign licensing agreement for compounds targeting FXR

Japanese approval for expanded use of Peg-Intron and Rebetol in HCV

Genzyme acquires gene therapy assets from Avigen

FTC clearance for Roche's licensing of BCX-4208

AtheroGenics and AstraZeneca sign agreement for AGI-1067

Bristol-Myers Squibb and Merck & Co. terminate muraglitazar agreement

Sinovac begins clinical testing of Panflu H5N1 vaccine

Enrollment update for AI-700 phase III program

Approval letter for Biovail's ODT formulation of citalopram hydrobromide

Orphan drug designation for eniluracil in liver cancer

Wyeth submits NDA for desvenlafaxine extended release

CT-32228 shows promise for treatment of imatinib-resistant CML

Phase II Cloretazine data presented

Quinoline and benzimidazole derivatives as potential candidates for presymptomatic diagnosis of AD

New D3 receptor antagonist exhibits antipsychotic properties in models of schizophrenia

Recent patents report novel analgesic agents

New therapeutic agents for skin disorders disclosed in recent Galderma patent

Recent patents report new therapeutic agents for diabetes and other endocrine-related disorders

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...